Lisata Therapeutics (LSTA) risk factors

82 risks, 7 new, 5 dropped, 12 reworded since the prior year. Lisata added a merger agreement risk with Kuva and updated going concern warnings. Cash reserves stand at $16.0 million.

80 risks. Lisata Therapeutics faces continuous net losses and significant future capital needs to fund ongoing clinical trials. The company depends on the clinical success and commercialization of its lead product candidate, certepetide. Operations rely heavily on third-party contract manufacturers and foreign research collaborations without internal commercial infrastructure.